2323 Chung Hsing

Release Date: June 23, 2026 Statement Date: June 22, 2026 Statement Time: 17:49:35 Company Code: 2323 Company Name: Chung Hsing Subject: Announcement of the Company's Acquisition of Securities Applicable Clause: Clause 20 Factual Date: June 22, 2026

1. Security Name: United Biomedical Common Stock

2. Transaction Date: June 17, 2026 – June 22, 2026

3. Board Approval Date: Not applicable

4. Other Approval Dates: Approval Level: Approved by Chairman June 22, 2026

5. Transaction Quantity, Unit Price, and Total Transaction Amount: Transaction Quantity (in thousands of shares): 140 Unit Price (NT$): 2,364.92 Total Transaction Amount (NT$): 331,088,541

6. Gain (or Loss) on Disposal (Not applicable for acquisition of securities): Not applicable

7. Relationship with the Target Company: None

8. Cumulative Holdings of the Security (including this transaction) to Date – Quantity, Amount, Ownership Percentage, and Rights Restrictions (e.g., Pledge): Holdings Balance: 235,000 shares, Amount: NT$582,652,177 Ownership Percentage: 0.25%, Rights Restrictions: None

9. Proportion of Securities Investments (including this transaction) under Article 3 of the “Regulations Governing the Acquisition or Disposition of Assets by Publicly Issued Companies” to Total Assets and Equity Attributable to Owners of Parent in the Most Recent Financial Statements, and the Amount of Working Capital in the Most Recent Financial Statements: Percentage of Total Assets: 82.21% Percentage of Equity Attributable to Owners of Parent: 118.07% Working Capital Amount: NT$8,285,327 thousand

10. Specific Purpose of Acquisition or Disposal: Investment Portfolio

11. Directors Who Expressed Objections to This Transaction: None

12. Whether This Transaction is a Related-Party Transaction: No

13. Counterparty and Its Relationship with the Company: Not applicable

14. Date of Supervisor’s Approval or Audit Committee’s Consent: Not applicable

15. Previous Date of Material Information Disclosure on the Same Event: Not applicable

16. Other Disclosures: On March 31, 2026, authorized trading personnel were granted permission to conduct securities transactions on the centralized market during the second quarter of 2026